Zobrazeno 1 - 10
of 156
pro vyhledávání: '"Maki Tanioka"'
Autor:
Yuki Kojima, Hiroshi Yoshida, Toshihiro Okuya, Hitomi S Okuma, Tadaaki Nishikawa, Maki Tanioka, Kazuki Sudo, Emi Noguchi, Tatsunori Shimoi, Kenji Tamura, Yasuhito Tanase, Masaya Uno, Mitsuya Ishikawa, Motoko Arakaki, Hitoshi Ichikawa, Shigehiro Yagishita, Akinobu Hamada, Yasuhiro Fujiwara, Kan Yonemori, Tomoyasu Kato
Publikováno v:
Gynecologic Oncology Reports, Vol 50, Iss , Pp 101302- (2023)
Background: Most cervical adenocarcinomas are associated with human papillomavirus (HPV). Gastric-type cervical adenocarcinoma (GAS), an HPV-independent adenocarcinoma, shows an aggressive clinical feature, resulting in a poor prognosis. Resistance t
Externí odkaz:
https://doaj.org/article/6ea628c1121a4c6caf801d05485e7145
Autor:
Shigemasa Takamizawa, Shu Yazaki, Yuki Kojima, Hiroshi Yoshida, Rui Kitadai, Tadaaki Nishikawa, Tatsunori Shimoi, Kazuki Sudo, Hitomi Sumiyoshi Okuma, Maki Tanioka, Emi Noguchi, Masaya Uno, Mitsuya Ishikawa, Tomoyasu Kato, Yasuhiro Fujiwara, Kan Yonemori
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Mesothelin (MSLN) is a cell-surface glycoprotein found in various solid tumours. Cancer therapies targeting MSLN have been developed in recent years; however, the available information on MSLN expression in cervical cancer is limi
Externí odkaz:
https://doaj.org/article/0d1ff421865b4a71af51806eb508282d
Autor:
Shigemasa Takamizawa, Tatsunori Shimoi, Natsuko Satomi-Tsushita, Shu Yazaki, Toshihiro Okuya, Yuki Kojima, Hitomi Sumiyoshi-Okuma, Tadaaki Nishikawa, Maki Tanioka, Kazuki Sudo, Emi Noguchi, Kan Yonemori
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Eribulin or capecitabine monotherapy is the next cytotoxic chemotherapy option for patients with metastatic or recurrent breast cancer who have previously received an anthracycline or a taxane. However, it is unclear what factors
Externí odkaz:
https://doaj.org/article/1a3d1d1d78eb446a83f9afbf76e57338
Autor:
Yuki Kojima, Emi Noguchi, Tomomi Yoshino, Shigehiro Yagishita, Shu Yazaki, Hitomi S. Okuma, Tadaaki Nishikawa, Maki Tanioka, Kazuki Sudo, Tatsunori Shimoi, Ayaka Kazama, Hiroshi Terasaki, Sachiro Asano, Yasuhiro Fujiwara, Akinobu Hamada, Kenji Tamura, Kan Yonemori
Publikováno v:
Diagnostics, Vol 13, Iss 12, p 2040 (2023)
Although circulating tumour DNA (ctDNA)-based next-generation sequencing (NGS) is a less invasive method for assessing ESR1 mutations that are essential mechanisms of endocrine therapy resistance in patients with oestrogen receptor-positive breast ca
Externí odkaz:
https://doaj.org/article/5c672b95ed7649a29f346277c875dfae
Autor:
Steven P. Angus, Timothy J. Stuhlmiller, Gaurav Mehta, Samantha M. Bevill, Daniel R. Goulet, J. Felix Olivares-Quintero, Michael P. East, Maki Tanioka, Jon S. Zawistowski, Darshan Singh, Noah Sciaky, Xin Chen, Xiaping He, Naim U. Rashid, Lynn Chollet-Hinton, Cheng Fan, Matthew G. Soloway, Patricia A. Spears, Stuart Jefferys, Joel S. Parker, Kristalyn K. Gallagher, Andres Forero-Torres, Ian E. Krop, Alastair M. Thompson, Rashmi Murthy, Michael L. Gatza, Charles M. Perou, H. Shelton Earp, Lisa A. Carey, Gary L. Johnson
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-15 (2021)
Abstract Inhibition of the HER2/ERBB2 receptor is a keystone to treating HER2-positive malignancies, particularly breast cancer, but a significant fraction of HER2-positive (HER2+) breast cancers recur or fail to respond. Anti-HER2 monoclonal antibod
Externí odkaz:
https://doaj.org/article/c11b8d70dbc348e48996b9c35fbb436b
Autor:
Arran K. Turnbull, Cigdem Selli, Carlos Martinez-Perez, Anu Fernando, Lorna Renshaw, Jane Keys, Jonine D. Figueroa, Xiaping He, Maki Tanioka, Alison F. Munro, Lee Murphy, Angie Fawkes, Richard Clark, Audrey Coutts, Charles M. Perou, Lisa A. Carey, J. Michael Dixon, Andrew H. Sims
Publikováno v:
BMC Bioinformatics, Vol 21, Iss 1, Pp 1-10 (2020)
Abstract Background High-throughput transcriptomics has matured into a very well established and widely utilised research tool over the last two decades. Clinical datasets generated on a range of different platforms continue to be deposited in public
Externí odkaz:
https://doaj.org/article/35931cd60eb849c58eee6a74c308610f
Publikováno v:
Cancer Research. 83:P3-07
Backgrounds: A liposomal formulation of Eribulin, E7389-LF may allow increased access to tumor tissues and has been under development for breast cancer. In a phase 1, expansion cohort as a late line treatment, objective response rate was observed to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e9e2d3b4695ddd91fd08cb81e97dc40
https://doi.org/10.1158/1538-7445.sabcs22-p3-07-03
https://doi.org/10.1158/1538-7445.sabcs22-p3-07-03
Autor:
Ayumi Saito, Maki Tanioka, Makoto Hirata, Tomoko Watanabe, Yoko Odaka, Tatsunori Shimoi, Kazuki Sudo, Emi Noguchi, Mitsuya Ishikawa, Kan Yonemori
Publikováno v:
Cancer Treatment and Research Communications, Vol 32, Iss , Pp 100587- (2022)
Background: BRCA1 c.5096G>A (p. Arg1699Gln) (hereinafter BRCA1 R1699Q) is classified as a pathogenic genetic variant despite its lower penetrance of breast and ovarian cancers compared to other BRCA1 variants. However, this mutation is currently repo
Externí odkaz:
https://doaj.org/article/c46f87c785ac4d55ac5a7bf7055e6597
Autor:
Hitomi Sumiyoshi Okuma, Kan Yonemori, Yuki Kojima, Maki Tanioka, Kazuki Sudo, Emi Noguchi, Susumu Hijioka, Keiko Wakakuwa, Ken Kato, Akihiro Hirakawa, Aya Kuchiba, Takashi Kubo, Hitoshi Ichikawa, Akihiko Yoshida, Yasushi Yatabe, Kenichi Nakamura, Hiroyuki Mano, Noboru Yamamoto, Yasuhiro Fujiwara
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
PurposePatients with advanced/relapsed rare cancers have few treatment options. Analysis of circulating tumor DNA in plasma may identify actionable genomic biomarkers using a non-invasive approach.Patients and MethodsRare cancer patients underwent pr
Externí odkaz:
https://doaj.org/article/35ecf0472ced44858aa96591a8e7fa2a
Autor:
Kin Yau Wong, Cheng Fan, Maki Tanioka, Joel S. Parker, Andrew B. Nobel, Donglin Zeng, Dan-Yu Lin, Charles M. Perou
Publikováno v:
Genome Biology, Vol 20, Iss 1, Pp 1-15 (2019)
Abstract We propose a statistical boosting method, termed I-Boost, to integrate multiple types of high-dimensional genomics data with clinical data for predicting survival time. I-Boost provides substantially higher prediction accuracy than existing
Externí odkaz:
https://doaj.org/article/cf9f5072a2aa4133b9f3e6be1fd292e1